Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1043)
All Articles published online
|
Publishing Process of This Article
|
Dec 27, 2025 (publication date) through Mar 30, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Panuganti VK, Alluri CV, Mohammad J, Dundigalla MR, Madala PK, KSSVV S, Shaik A. Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. World J Hepatol 2025; 17(12): 113658 [PMID: 41479524 DOI: 10.4254/wjh.v17.i12.113658] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Panuganti VK, Alluri CV, Mohammad J, Dundigalla MR, Madala PK, KSSVV S, Shaik A. Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. World J Hepatol 2025; 17(12): 113658 [PMID: 41479524 DOI: 10.4254/wjh.v17.i12.113658] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i12/113658.htm |
| Number | Citing Articles |
| 1 |
Nor-ursodeoxycholic acid for metabolic dysfunction-associated steatotic liver disease: is there enough evidence for clinical use? A critique of a phase III trial and regulatory endorsement of the drug. Journal of Clinical and Experimental Hepatology 2026; : 103536 doi: 10.1016/j.jceh.2026.103536
|